>>Signaling Pathways>> Cell Cycle/Checkpoint>> Kinesin>>AZ82

AZ82

Catalog No.GC18956

AZ82는 KIFC1에 대해 Ki가 43nM이고 IC50이 300nM인 선택적 키네신 유사 단백질 KIFC1(HSET/KIFC1) 억제제입니다.

Products are for research use only. Not for human use. We do not sell to patients.

AZ82 Chemical Structure

Cas No.: 1449578-65-7

Size 가격 재고 수량
1mg
US$42.00
재고 있음
5mg
US$234.00
재고 있음
10mg
US$356.00
재고 있음
25mg
US$712.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

AZ82 is a small molecule inhibitor of KIFC1/HSET, a kinesin-14 family protein that is important for assembling bipolar spindles in cancer cells containing supernumerary centrosomes.[1]  AZ82 binds to the KIFC1/microtubule complex and inhibits its microtubule-stimulated activity (IC50 = 300 nM) in an ATP-competitive (Ki = 43 nM) and microtubule-noncompetitive manner but does not inhibit basal KIFC1 activity at a concentration of 100 uM. [2] It is selective for KIFC1 over a panel of nine kinesin motor proteins at a concentration of 5 uM. AZ82 induces multipolar spindle formation in cancer cell lines with high (BT549), but not low (HeLa and MCF-7), numbers of extra chromosomes.

Reference:
[1]. Godinho, S.A., and Pellman, D. Causes and consequences of centrosome abnormalities in cancer. Philos. Trans. R. Soc. Lond. B Biol. Sci. 369(1650), pii: 20130467 (2014).
[2]. Wu, J., Mikule, K., Wang, W., et al. Discovery and mechanistic study of a small molecule inhibitor for motor protein KIFC1. ACS Chem. Biol. 8(10), 2201-2208 (2013).

리뷰

Review for AZ82

Average Rating: 5 ★★★★★ (Based on Reviews and 2 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for AZ82

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.